Shares of Sangamo Biosciences (SGMO -0.9%) slip after SEC filings show the company's CEO and CFO...


Shares of Sangamo Biosciences (SGMO -0.9%) slip after SEC filings show the company's CEO and CFO both sold shares of the company.
From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (566) | Send Message
     
    The slip of .9% had nothing to do with the stock sales of management.
    These were planned sales established last year. For a company that has appreciated in price from a 14 month low of $2.43 to the recent high of $10.05, what effect should a .25 dip make. it happens in the market and SGMO every spring. A slight dip from the very rapid uptrun is expected. Until the results of SGMO PH I and PH I/II results and early reports of the 1 year long 2 PH II HIV trials.
    Key component of this years research reports will come at the ASCGT in May, stemcell updates from UCSD and COH.
    e wait, we fluctuate.
    29 Jan 2013, 08:50 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs